Embryonic stem cells: what are they?

Embryonic stem cells are derived from the inner cell mass of the early blastocyst at a very early stage of development. These cells are pluripotent, meaning they can differentiate into all cell types in the body. However, they do not form a fully developed organism without external embryonic structures. This distinguishes them from the totipotent cells of the earliest stages of embryogenesis. This biological profile makes embryonic stem cells a valuable model tool and a potential basis for tissue replacement. [1]

The emergence of induced pluripotent cells, obtained by reprogramming mature somatic cells, has created an alternative with functional capabilities similar to embryonic stem cells. However, a number of differences remain: embryonic stem cell lines have different epigenetic memory and a different differentiation profile, while induced pluripotent cells carry epigenetic traces of the original tissue and the risks associated with reprogramming. In clinical translation, this impacts reproducibility and quality control requirements. [2]

Clinical interest in embryonic stem cells stems from the potential to produce virtually unlimited quantities of standardized, specialized cells. The most active areas of research are the retina, pancreas, and nervous system. These areas rely on targeted differentiation protocols and strict criteria for releasing products before administration to patients. [3]

A significant body of clinical trials of cell products derived from pluripotent stem cells has now accumulated worldwide. A systematic review of the status as of the end of 2024 identified over a hundred trials with regulatory approval and dozens of different products. This confirms the shift from conceptual studies to testing for real-world clinical benefit and safety. [4]

Table 1. Pluripotent and adult stem cells: key differences

Criterion	Embryonic stem cells	Induced pluripotent stem cells	Adult stem cells
Source	Inner cell mass of the blastocyst	Reprogramming of mature cells	Tissues of the adult organism
Differentiation potential	Pluripotency	Pluripotency	Limited, tissue-specific
Ethical issues	Yes, they involve the use of embryos.	Significantly lower	Minimal
Reproducibility of lines	High in standardization	Depends on the reprogramming technique	Limited by fabric availability
Typical risks	Tumor formation with the admixture of undifferentiated cells	Genetic-epigenetic instability during reprogramming	Low differentiation power

How are the lines produced and how is quality controlled?

Cell line creation begins with the isolation of the inner cell mass and its transfer to culture. Modern protocols strive for xeno-free and fully defined conditions, which is important for subsequent clinical application. During the development stage, target cells are defined, stages of directed differentiation, and protocols for purification from undifferentiated subpopulations are developed. [5]

Quality control includes verification of identity, sterility, the absence of adventitious agents, genetic stability, and functional testing. For pluripotent products, it is critical to confirm the absence of residual pluripotent cells, which increase the risk of tumorigenesis, as well as to assess biodistribution and phenotypic stability after transplantation. Regulators and specialized societies are developing expected approaches to preclinical evaluation. [6]

Cell product manufacturing is standardized according to good manufacturing practices. Validation of key stages and clear release criteria reduce batch-to-batch variability. The success of a clinical program directly depends on discipline in manufacturing, as even minor deviations in culture media and culture conditions can alter the properties of the final product. [7]

As the number of technologies grows, greater attention is being paid to reproducibility between centers. Consensus lists of quality attributes and standard reporting forms are emerging, improving the comparability of results. [8]

Table 2. Critical quality attributes for embryonic stem cell products

Attribute	What do they check?	Why is this necessary?
Identity	Phenotype markers and lineages	Confirm target cell type compliance
Purity	Absence of undifferentiated cells and unwanted impurities	Reduce the risk of tumor formation and ectopic differentiation
Sterility	Bacteria, fungi, mycoplasma, viruses	Prevent infectious complications
Genetic stability	Karyotype, point mutations, structural rearrangements	Ensure security and predictability
Functionality	Tissue-specific activity tests in vitro and in models	Confirm clinical relevance

Regulatory and ethical context

In the United States, the National Institutes of Health has formal guidelines for research involving human embryonic stem cells and accompanying oversight mechanisms for the use of federal funds. These are not therapy approvals, but rather a framework for ethical and scientifically sound work. [9]

The International Society for Stem Cell Research updated its guidelines for stem cell-based embryo models in 2025. The document strengthened oversight recommendations and prohibited any attempts to implant model structures or grow them to viable stages, while acknowledging the scientific value of these systems for understanding early development. [10]

In the UK, the regulator for reproductive medicine is discussing revising the historical restriction on research on real embryos in culture from 14 to 28 days, subject to strict conditions and individual approvals. This reflects the technical feasibility of reaching later stages of development and the scientific need to better understand the causes of early pregnancy loss and birth defects. This does not automatically imply relaxations, but it does indicate the direction of the discussion. [11]

In 2024, the European Union adopted a new pan-European regulation on substances of human origin, which consolidates and updates regulations on cells and tissues, raising quality and safety standards and strengthening coordination with regulations on advanced therapeutic products. This is an important basis for the future clinical application of cell technologies. [12]

Table 3. Regulatory framework for research and therapy

Jurisdiction	Document or body	Key positions for embryonic stem cells
United States	National Institutes of Health guidelines	Ethical framework for research and lists of acceptable lines of research
International scientific community	The International Society for Stem Cell Research Guidelines, 2025 Update	Increased surveillance of model embryo structures and a ban on implantation attempts
United Kingdom	The regulator is discussing a possible extension of the limit to 28 days.	Possible change of the legally fixed limit under strict control
European Union	Substances of Human Origin Regulations 2024	Uniform high standards of quality and safety of cells and tissues

Where the Clinic is Heading: Trial Directions and Their Status

In ophthalmology, clinical trials are underway to transplant retinal pigment epithelial cells derived from embryonic stem cells. Several programs have demonstrated sustained structural and functional improvements in vision over periods of up to thirty-six months of follow-up in patients with geographic atrophy associated with age-related macular degeneration. This is an important signal of the clinical feasibility of this approach. [13]

In diabetology, the replacement of insulin-producing cells derived from pluripotent sources and differentiated into islet cells is being evaluated. A study of the drug zimizlesel reported stable cell engraftment, restoration of insulin production, and a reduction in the need for exogenous insulin in the full-dose group. The method remains investigational and requires immunosuppression, but it demonstrates evidence of a mechanism of action. [14]

In neurology, oligodendrocyte precursors from embryonic stem cells have been studied in spinal cord injury. Early results indicated safety and possible functional benefit, although the program remains in the research phase and requires further optimization. [15]

As of autumn 2025, registry reviews document over a hundred clinical trials of products from pluripotent stem cells across a wide range of indications. However, there are no general market approvals specifically for embryonic stem cell products in major jurisdictions. Approvals apply to other classes of cell and gene technologies, as well as hematopoietic and umbilical cord products. This soberingly reflects the complexity of the technological and regulatory pathway for embryonic stem cells. [16]

Table 4. Clinical applications of embryonic stem cell products

Direction	Product example	The goal of therapy	Current status
Retina	Retinal pigment epithelium from embryonic stem cells	Slowing down atrophy and improving function	Long-term observation with sustained effect in the early phases
Type 1 diabetes	Islet cells from a pluripotent source	Restoration of endogenous insulin secretion	Positive phase 1-2 results, evaluation ongoing
Spinal cord	Oligodendrocyte precursors	Remelinization and restoration of conductivity	Early stages, further optimization required

Risks and how they are mitigated in practice

The main specific risk for embryonic stem cell products is tumorigenesis in the presence of even a small amount of undifferentiated cells. Therefore, multi-tiered purification and testing strategies are employed, including molecular markers, functional assays, and biodistribution modeling. Only batches that meet purity and safety criteria are released into the clinic. [17]

Immunological risks are associated with the allogeneic nature of the cells and the need to prevent rejection. This entails immunosuppression for a certain period and systemic monitoring for infectious complications. Simultaneously, engineering approaches to reducing immunogenicity and selecting optimal concomitant therapy regimens are being explored. [18]

Technological risks include genetic and epigenetic instability during long-term cultivation, batch-to-batch variability, and inconsistency between functional properties and claims. Practice-based biosafety frameworks translate these risks into operational principles with clear tests and tolerances. [19]

Finally, there are systemic risks associated with unregulated offerings of pseudo-therapies on the commercial market. This requires careful review of centers, product status, and compliance with legislation and regulatory frameworks. [20]

Table 5. Risks and practical mitigation measures

Risk	What is the point?	What are they doing?
Tumor formation	Admixture of pluripotent cells	Deep purification, residual pluripotency markers, biodistribution tests
Immune rejection	Allogeneic cells are recognized by the immune system	Immunosuppression according to protocol, infection monitoring, search for engineering solutions
Genetic instability	Changes during long-term cultivation	Karyotyping, sequencing as indicated, passage limitation
Variability of parties	Differences in production parameters	Standardized environments and modes, validation of critical stages
Unregulated market	Commercial proposals without evidence	Check product status, participate only in approved studies

What is really available to patients today?

Hematopoietic stem cell transplants and a number of approved gene and cell technologies of other classes are routinely used. Clinical trials for embryo-derived products are ongoing, but there are no general market approvals in leading jurisdictions. In Europe, a product based on umbilical cord cells and not derived from embryonic sources will be approved in 2025 to expand access to transplantation in the absence of a suitable donor. It is important to distinguish between these two to avoid inflated expectations and unscrupulous offers. [21]

In the United States, official listings confirm approvals for individual gene and cell products, as well as for umbilical cord blood products, but not for embryonic stem cell products. Patients and physicians are advised to check product status in public registries and on regulatory websites. [22]

Table 6. How to distinguish legitimate therapy from pseudotherapy

Verification step	What to look for	Where to watch
Regulatory status	Availability of marketing approval or active approved research	Regulatory websites and clinical trial registries
Legal jurisdiction	Compliance with local laws and practices	Official resources of the country and specialized societies
Center documentation	Protocol, risk information, patient consent	Center documents and independent reviews
Publications	Peer-reviewed safety and efficacy data	Publication databases and conference reports
Promises	Realistic goals without a guarantee of cure	Sound critical analysis

Prospects and fair limitations

The most advanced areas for embryonic-derived products today are retina and islet cells. In both cases, there are already demonstrations of long-term engraftment and functional effects in the early stages, but challenges remain regarding immunosuppression, long-term safety, and industrial reproducibility. [23]

In the coming years, standardization of production and harmonization of requirements across jurisdictions will play a crucial role. The new European Regulation on Substances of Human Origin establishes uniform quality and safety standards and could accelerate the transition from laboratory to clinic. International guidelines and updates on embryo models establish clear boundaries for research and strengthen public trust. [24]

Competition with induced pluripotent stem cells will remain, as these technologies potentially reduce ethical concerns and enable the creation of customized products. In practice, approaches likely coexist with indication selection, where the advantages of embryonic-derived products outweigh the benefits. [25]

Patients and clinicians should rely on evidence, carefully weigh the risks and benefits, and consider participating in centers with transparent monitoring protocols and long-term follow-up. This is the most reliable strategy during a period when the potential is already visible and widespread availability is yet to come. [26]